Mixture of HMOS for treating wheat sensitivity
The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for the treatment of, secondary prevention of, and/or induction of tolerance to non-coeliac wheat and/or gluten sensitivity in a human.
1. A method of inducing wheat and/or gluten tolerance in a human patient suffering from non-coeliac wheat and/or gluten sensitivity comprising administering at least one human milk oligosaccharides (HMO) to the patient,
wherein the at least one HMO comprises 2′-FL, DFL, LNT, or LNnT.
2. The method according to claim 1 , wherein the at least one HMO is administered in a synthetic composition.
3. The method according to claim 2 , wherein the synthetic composition comprises an amount of 1 g to 15 g of the at least one HMO.
4. The method according to claim 1 , wherein the at least one HMO further comprises 3′-SL, 6′-SL, LNFP-I, or a mixture thereof.
5. The method according to claim 1 , wherein the at least one HMO is a mixture of a fucosylated HMO and a non-fucosylated HMO.
6. The method according to claim 5 , wherein the mixture comprises at least one of 2′-FL and DFL, and at least one of LNnT and LNT.
7. The method according to claim 6 , wherein the mixture comprises 2′-FL and LNnT.
8. The method according to claim 1 , wherein the patient is administered an amount of 3 g to 15 g per day of the at least one HMO.
9. The method according to claim 1 , wherein at least one HMO is administered to the human for at least 7 consecutive days.
10. The method according to claim 1 , in which the patient is administered the at least one HMO while consuming gluten containing cereals.
11. The method according to claim 1 , the method comprises administering the at least one HMO at a first dose in a first phase to treat non-coeliac wheat and/or gluten sensitivity and administering the at least one HMO at a second dose in a second phase for inducing the wheat and/or gluten tolerance.
12. The method according to claim 11 , in which the patient is administered a higher dose of HMO during the first phase followed by a lower dose of HMO during the second phase.
13. The method according to claim 12 , in which the higher dose is about 3 g to about 15 g per day and the lower dose is about 2 g to about 7.5 g per day.
14. The method according to claim 11 , wherein the duration of the first phase is at least consecutive 7 days, and the duration of the second phase is at least four consecutive weeks.
15. The method according to claim 3 , wherein the synthetic composition comprises an amount of 2 g to 10 g of the at least one HMO.
16. The method according to claim 3 , wherein the synthetic composition comprises an amount of 3 g to 7 g of the at least one HMO.
17. The method according to claim 7 , wherein the 2′-FL and LNnT in the mixture are in a mass ratio of 4:1 to 1:1.
18. The method according to claim 8 , wherein the patient is administered about 4 g to about 7.5 g of the at least one HMO per day.
19. The method according to claim 13 , in which the higher dose is about 4 g to about 7.5 g per day and the lower dose is about 2 g to about 5 g per day.